It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Alnylam Files Patisiran in Japan, Anticipates Nod in Mid-2019
October 2, 2018
- Astellas Seeks Approval for Japan’s 1st HIF-PH Inhibitor Roxadustat
October 2, 2018
- Wholesalers See “Some Reduction in Yakkasa” in Price Negotiations under New Guidelines: Will Reduction Continue?
October 2, 2018
- Maruho Licenses Cancer Stomatitis Treatment from NCC
October 2, 2018
- Konica Minolta Embarks on Precision Medicine Biz, Ex-GSK/AZ Exec Takes Helm
October 1, 2018
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- Maruho Takes Over Differin Gel Marketing Authorization from Galderma
October 1, 2018
- Vortioxetine Filed in Japan for MDD: Takeda/Lundbeck
October 1, 2018
- Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
October 1, 2018
- 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
October 1, 2018
- Takeda Touts Progress in R&D Makeover, Departure from Small Molecules
September 28, 2018
- Kyorin, Teijin Dissolve Capital Alliance
September 28, 2018
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
- Number of Sales Reps in 43 Pharmas Dwindles by 4,906 in 4 Years: Survey
September 28, 2018
- Daiichi Sankyo Begins PIII Breast Cancer Trials for DS-8201
September 27, 2018
- IBM Japan Joins Takeda’s Shonan iPark
September 27, 2018
- Celgene Seeks Japan OK for Pomalyst Triplet for MM
September 27, 2018
- Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
September 27, 2018
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- Takeda’s Brigatinib Snags European Panel OK for 2nd Line ALK-Positive NSCLC
September 26, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…